Shares in Imago more than doubled in the wake of the announcement to approach the offer price, hovering around $35.60 at the time of writing. Image. Phil Taylor. 21 November, 2022.

MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (MPNs).